Viemed Healthcare, Inc.
NASDAQ:VMDMedical - Devices
+$0.07 today
- Market cap
- $332.70M
- Beta
- 1.13
- P/E (TTM)
- 27.4
- EPS (TTM)
- $0.39
Volume 0.26M
Average 0.26M
VMD Other Financing Activities
Financing cash flows not reported separately.
Viemed Healthcare, Inc.NASDAQ: VMD
Other Financing Activities · Q1 FY2026 · quarter ended Mar 2026
Other financing activities turns negative
Q1 FY2026 other financing activities was -$2.17M, compared with $11K a year earlier. Trailing-twelve-month other financing activities was -$2.65M.
Context
- Other financing activities amounted to 0.8% of revenue in FY2025, up 0.4 pp from a year earlier.
- Other financing activities increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly other financing activities holds near -$2.17M or moves back toward the trailing-twelve-month quarterly average of -$663K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Other Financing Activities history
USD · from the cash flow
- Latest · FY2025
- (2.16M) USD
- Year-over-year change
- -373.5%
| Period | Period end | Other Financing Activities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (2.16M) | -373.5% |
| FY2024 | 2024-12-31 | 789K | -39.4% |
| FY2023 | 2023-12-31 | 1.3M | +360.4% |
| FY2022 | 2022-12-31 | 283K | +152.7% |
| FY2021 | 2021-12-31 | 112K | — |
Other Financing Activities vs competitors
How VMD compares with its peers on the latest reported figures
- VMD's LTM Mar 2026 other financing activities of $2.65M is the 3rd largest of the 11 companies compared; the peer median is $95.5K.
- Its year-over-year change of -634.7% is the lowest of 10, against a peer median of -73.4%.
- Other financing activities amounts to 0.9% of revenue for VMD, versus a peer median of 0.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Dec 2025 | $5.82M | +10455.5% | — | 44.7% | |
| LTM Mar 2026 | $3.49M | +850.1% | +61.0% | 6.0% | |
| LTM Mar 2026 | $2.65M | -634.7% | — | 0.9% | |
| LTM Mar 2026 | $2.22M | -80.7% | +13.1% | 5.4% | |
| LTM Mar 2026 | $1.47M | -15.9% | — | 1.0% | |
| LTM Mar 2026 | $873K | -73.4% | +43.4% | 0.2% | |
| LTM Mar 2026 | $118K | -101.0% | — | 0.3% | |
| LTM Mar 2026 | $73K | -96.5% | +190.1% | 0.1% | |
| LTM Mar 2026 | $5K | +101.6% | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | -100.0% | — | 0.0% | |
| Peer median (excluding VMD) | $95.5K | -73.4% | +52.2% | 0.3% | |
Competitors are the stored peer set for VMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 9.13M | 6.22M | 10.24M | 11.41M | 14.93M |
| Depreciation & Amortization | 11.31M | 15.63M | 21.86M | 25.37M | 28.61M |
| Deferred Income Tax | 3.88M | 1.75M | (1.44M) | (3.84M) | 3.11M |
| Stock-Based Compensation | 5.15M | 5.2M | 5.85M | 6.29M | 9.13M |
| Change in Working Capital | (13.56M) | (10.14M) | 7.78M | 355K | (2.3M) |
| Accounts Receivables | (7.35M) | (12.57M) | (1.08M) | (6.07M) | 1.16M |
| Inventory | (212K) | 301K | (480.66K) | 574K | 59K |
| Accounts Payables | 133K | (318K) | (874.75K) | 359K | 479K |
| Other Working Capital | (6.14M) | 2.45M | 10.21M | 5.5M | (4M) |
| Other Non-Cash Items | 6.58M | 9.08M | 921K | (488K) | (1.57M) |
| Operating Cash Flow | 22.49M | 27.75M | 45.21M | 39.09M | 51.92M |
| Capital Expenditures | (19.74M) | (22.9M) | (26.09M) | (37.77M) | (39.99M) |
| Acquisitions (Net) | (599K) | (141K) | (28.59M) | (3M) | (26.33M) |
| Purchases of Investments | (593.73K) | (2M) | 0 | 0 | 0 |
| Sales of Investments | 593.73K | 0 | 0 | 750K | 0 |
| Other Investing Activities | 596K | 1.06M | 2.57M | 9.32M | 16.15M |
| Investing Cash Flow | (19.75M) | (23.98M) | (52.11M) | (30.7M) | (50.17M) |
| Debt Repayment | (4M) | (5.84M) | 2.12M | (3.41M) | 8.15M |
| Common Stock Issued | 0 | 0 | 0 | 0 | 1.44M |
| Common Stock Repurchased | (1.43M) | (9.71M) | (594K) | (1.07M) | (13.23M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 112K | 283K | 1.3M | 789K | (2.16M) |
| Financing Cash Flow | (5.32M) | (15.27M) | 2.83M | (3.69M) | (5.79M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (2.57M) | (11.49M) | (4.08M) | 4.7M | (4.04M) |
| Free Cash Flow | 2.75M | 4.85M | 19.12M | 1.32M | 11.93M |
Viemed Healthcare, Inc.
NASDAQ:VMD
Intrinsic Alpha fair value
Locked
Current Price
$8.78
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.